Related Experiment Video
Updated: Jan 3, 2026
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status
Fadi Abdel-Sater1, Mehdi Najar2, Hussein Fayyad-Kazan1,3
1Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences I, Lebanese University, Hadath, Lebanon.
Abstract:
Triple-negative breast cancer (TNBC) represents 15% of breast carcinomas. More than 80% of women with a breast cancer associated with a breast cancer type 1 (BRCA1) mutation develop a TNBC. microRNAs (miRNAs) play critical roles in diverse biological processes and are aberrantly expressed in several human neoplasms including breast cancer, where they function as actors of tumor onset, behavior, and progression. However, an extensive microRNA profile has not yet been determined for TNBC. Taqman low-density arrays (TLDAs) were used to screen the expression level of 667 miRNAs in TNBC versus normal breast tissues. Our TLDA results revealed 20 differentially expressed miRNAs among which 14 (10 upregulated and four downregulated) were confirmed by an individual quantitative real-time polymerase chain reaction. Interestingly, a novel link between BRCA1 status and miRNA expression level was identified through miR-96 and miR-10b that were very important discriminators between TNBC with mutated BRCA1 and TNBC with wild type BRCA1. This study promises discoveries of new pathological pathways at work in this dreadful disease and clearly warrants validation in large prospective studies with the aim of identifying novel biomarkers for diagnosis and targets for clinical interventions.
Insights
Triple-negative breast cancer (TNBC) research identified differentially expressed microRNAs (miRNAs). Specific miRNAs like miR-96 and miR-10b distinguish between BRCA1-mutated and wild-type TNBC, offering potential diagnostic biomarkers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Triple-negative breast cancer (TNBC) accounts for 15% of breast cancer cases.
- Over 80% of women with BRCA1 mutations develop TNBC.
- MicroRNAs (miRNAs) are crucial in cancer development and progression, but their profile in TNBC is not fully understood.
Purpose of the Study:
- To comprehensively profile microRNA (miRNA) expression in triple-negative breast cancer (TNBC).
- To identify specific miRNAs that differentiate TNBC with BRCA1 mutations from those without.
- To explore potential new diagnostic biomarkers and therapeutic targets for TNBC.
Main Methods:
- Screening of 667 miRNAs using Taqman low-density arrays (TLDAs) in TNBC versus normal breast tissues.
- Confirmation of differentially expressed miRNAs using quantitative real-time polymerase chain reaction (qRT-PCR).
- Analysis of miRNA expression in relation to BRCA1 mutation status.
Main Results:
- Identified 20 differentially expressed miRNAs between TNBC and normal breast tissues.
- Confirmed 14 of these miRNAs (10 upregulated, 4 downregulated) via qRT-PCR.
- Discovered miR-96 and miR-10b as key discriminators between TNBC with mutated BRCA1 and wild-type BRCA1.
Conclusions:
- This study provides a detailed miRNA expression profile for TNBC.
- miR-96 and miR-10b show potential as biomarkers for distinguishing BRCA1-mutated TNBC.
- Further validation in large prospective studies is needed to establish diagnostic and therapeutic utility.
More Related Videos
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs